Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma

Kristen N. Ganjoo, Rebecca Chan, Matt Sharma, Lawrence Einhorn

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Purpose: To assess the ability of positron emission tomography (PET) scans in differentiating between necrosis and viable seminoma in postchemotherapy (PC) residual disease. Patients and Methods: We conducted a prospective study of 29 patients with seminoma at Indiana University. All patients had PC residual disease. Computed tomography and PET scans were performed for 19 patients after primary chemotherapy (group A) and for 10 patients after salvage chemotherapy (group B). Results: In group A, the PC masses were ≥ 3 cm in 14 patients, less than 3 cm in three patients, and not quantified in two patients. All of the patients in group A had negative PET scan results and have had stable or decreasing residual mass size (median follow-up duration, 11.5 months; range, 6 to 26 months). In group B, the PC masses were ≥ 3 cm in four patients, less than 3 cm in five patients, and not quantified in one patient. One patient had a positive PET scan result for a posterior mediastinal mass. Pathologic diagnosis of the PET-positive mass showed only necrotic tissue. The same patient had a negative PET scan of the retroperitoneal mass but relapsed in that area. Overall, of patients in group B, five have stable or decreasing mass (median follow-up duration, 8 months; range, 7 to 22 months), and five had relapsed disease. Conclusion: PET scans have no apparent benefit in PC evaluation of residual masses in bulky seminoma.

Original languageEnglish
Pages (from-to)3457-3460
Number of pages4
JournalJournal of Clinical Oncology
Volume17
Issue number11
StatePublished - Nov 1999

Fingerprint

Seminoma
Positron-Emission Tomography
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. / Ganjoo, Kristen N.; Chan, Rebecca; Sharma, Matt; Einhorn, Lawrence.

In: Journal of Clinical Oncology, Vol. 17, No. 11, 11.1999, p. 3457-3460.

Research output: Contribution to journalArticle

@article{2e1071a217eb4a2dacec0f64fea43fa8,
title = "Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma",
abstract = "Purpose: To assess the ability of positron emission tomography (PET) scans in differentiating between necrosis and viable seminoma in postchemotherapy (PC) residual disease. Patients and Methods: We conducted a prospective study of 29 patients with seminoma at Indiana University. All patients had PC residual disease. Computed tomography and PET scans were performed for 19 patients after primary chemotherapy (group A) and for 10 patients after salvage chemotherapy (group B). Results: In group A, the PC masses were ≥ 3 cm in 14 patients, less than 3 cm in three patients, and not quantified in two patients. All of the patients in group A had negative PET scan results and have had stable or decreasing residual mass size (median follow-up duration, 11.5 months; range, 6 to 26 months). In group B, the PC masses were ≥ 3 cm in four patients, less than 3 cm in five patients, and not quantified in one patient. One patient had a positive PET scan result for a posterior mediastinal mass. Pathologic diagnosis of the PET-positive mass showed only necrotic tissue. The same patient had a negative PET scan of the retroperitoneal mass but relapsed in that area. Overall, of patients in group B, five have stable or decreasing mass (median follow-up duration, 8 months; range, 7 to 22 months), and five had relapsed disease. Conclusion: PET scans have no apparent benefit in PC evaluation of residual masses in bulky seminoma.",
author = "Ganjoo, {Kristen N.} and Rebecca Chan and Matt Sharma and Lawrence Einhorn",
year = "1999",
month = "11",
language = "English",
volume = "17",
pages = "3457--3460",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma

AU - Ganjoo, Kristen N.

AU - Chan, Rebecca

AU - Sharma, Matt

AU - Einhorn, Lawrence

PY - 1999/11

Y1 - 1999/11

N2 - Purpose: To assess the ability of positron emission tomography (PET) scans in differentiating between necrosis and viable seminoma in postchemotherapy (PC) residual disease. Patients and Methods: We conducted a prospective study of 29 patients with seminoma at Indiana University. All patients had PC residual disease. Computed tomography and PET scans were performed for 19 patients after primary chemotherapy (group A) and for 10 patients after salvage chemotherapy (group B). Results: In group A, the PC masses were ≥ 3 cm in 14 patients, less than 3 cm in three patients, and not quantified in two patients. All of the patients in group A had negative PET scan results and have had stable or decreasing residual mass size (median follow-up duration, 11.5 months; range, 6 to 26 months). In group B, the PC masses were ≥ 3 cm in four patients, less than 3 cm in five patients, and not quantified in one patient. One patient had a positive PET scan result for a posterior mediastinal mass. Pathologic diagnosis of the PET-positive mass showed only necrotic tissue. The same patient had a negative PET scan of the retroperitoneal mass but relapsed in that area. Overall, of patients in group B, five have stable or decreasing mass (median follow-up duration, 8 months; range, 7 to 22 months), and five had relapsed disease. Conclusion: PET scans have no apparent benefit in PC evaluation of residual masses in bulky seminoma.

AB - Purpose: To assess the ability of positron emission tomography (PET) scans in differentiating between necrosis and viable seminoma in postchemotherapy (PC) residual disease. Patients and Methods: We conducted a prospective study of 29 patients with seminoma at Indiana University. All patients had PC residual disease. Computed tomography and PET scans were performed for 19 patients after primary chemotherapy (group A) and for 10 patients after salvage chemotherapy (group B). Results: In group A, the PC masses were ≥ 3 cm in 14 patients, less than 3 cm in three patients, and not quantified in two patients. All of the patients in group A had negative PET scan results and have had stable or decreasing residual mass size (median follow-up duration, 11.5 months; range, 6 to 26 months). In group B, the PC masses were ≥ 3 cm in four patients, less than 3 cm in five patients, and not quantified in one patient. One patient had a positive PET scan result for a posterior mediastinal mass. Pathologic diagnosis of the PET-positive mass showed only necrotic tissue. The same patient had a negative PET scan of the retroperitoneal mass but relapsed in that area. Overall, of patients in group B, five have stable or decreasing mass (median follow-up duration, 8 months; range, 7 to 22 months), and five had relapsed disease. Conclusion: PET scans have no apparent benefit in PC evaluation of residual masses in bulky seminoma.

UR - http://www.scopus.com/inward/record.url?scp=0032728818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032728818&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 3457

EP - 3460

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -